Cargando…
Liver Activation of Hepatocellular Nuclear Factor-4α by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile
Non-alcoholic fatty liver disease (NAFLD) culminates in insulin resistance and metabolic syndrome. Because there are no approved pharmacological treatment agents for non-alcoholic steatohepatitis (NASH) and NAFLD, different signaling pathways are under investigation for drug development with the foc...
Autores principales: | Huang, Kai-Wen, Reebye, Vikash, Czysz, Katherine, Ciriello, Simona, Dorman, Stephanie, Reccia, Isabella, Lai, Hong-Shiee, Peng, Ling, Kostomitsopoulos, Nikos, Nicholls, Joanna, Habib, Robert S., Tomalia, Donald A., Sætrom, Pål, Wilkes, Edmund, Cutillas, Pedro, Rossi, John J., Habib, Nagy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938799/ https://www.ncbi.nlm.nih.gov/pubmed/31877412 http://dx.doi.org/10.1016/j.omtn.2019.10.044 |
Ejemplares similares
-
Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer
por: Reebye, Vikash, et al.
Publicado: (2018) -
Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo
por: Yoon, Sorah, et al.
Publicado: (2016) -
A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34(+) Cells
por: Reebye, Vikash, et al.
Publicado: (2013) -
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer
por: Voutila, Jon, et al.
Publicado: (2017) -
Exploiting Human CD34(+) Stem Cell–conditioned Medium for Tissue Repair
por: Mintz, Paul J, et al.
Publicado: (2014)